Clindamycin Pledget
Name: Clindamycin Pledget
Indications and Usage for Clindamycin Pledget
Clindamycin Phosphate Topical Solution USP, 1% is indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate (see CONTRAINDICATIONS, WARNINGS and ADVERSE REACTIONS).
Contraindications
Clindamycin Phosphate Topical Solution USP, 1% is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.
Adverse Reactions
In 18 clinical studies of various formulations of topical clindamycin phosphate using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatologic events [see table below].
Number of Patients Reporting Events | |||
Treatment Emergent | Solution | Gel | Lotion |
Adverse Event | n=553 (%) | n=148(%) | n=160(%) |
Burning | 62 (11) | 15 (10) | 17 (11) |
Itching | 36 (7) | 15 (10) | 17 (11) |
Burning/Itching | 60 (11) | # (-) | # (-) |
Dryness | 105 (19) | 34 (23) | 29 (18) |
Erythema | 86 (16) | 10 (7) | 22 (14) |
Oiliness/Oily Skin | 8 (1) | 26 (18) | 12* (10) |
Peeling | 61 (11) | # (-) | 11 (7) |
# not recorded | |||
* of 126 subjects |
Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally. Cases of diarrhea, bloody diarrhea and colitis (including pseudomembranous colitis) have been reported as adverse reactions in patients treated with oral and parenteral formulations of clindamycin and rarely with topical clindamycin (see WARNINGS).
Abdominal pain, gastrointestinal disturbances, gram-negative folliculitis, eye pain and contact dermatitis have also been reported in association with the use of topical formulations of clindamycin.
Clindamycin Pledget Dosage and Administration
Do not use if the seal on jar is broken. Remove pledget from jar just before use. Use a pledget to apply a thin film of Clindamycin Phosphate Topical Solution to the affected area twice daily. More than one pledget may be used. Each pledget should be used only once and then discarded. Keep jar tightly closed when not in use. (Jar Configuration)
Do not use if the unit-dose pouch seal is broken. Remove pledget just before use. Use pledget to apply a thin film of Clindamycin Phosphate Topical Solution to the affected area twice daily. More than one pledget may be used. Each pledget should be used only once and then discarded. (Individually Wrapped Pledget Configuration)
Storage
Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature]. Protect from freezing.
Manufactured By
Perrigo
Bronx, NY 10457
Distributed By Perrigo
Allegan, MI 49010
www.perrigo.com
:0T900 RC J6 (Perrigo part number for jar configuration insert)
:0T900 RC J7 (Perrigo part number for Individually Wrapped Pledget configuration insert)
Rev 02-16
Principal Display Panel
Clindamycin Phosphate Topical Solution USP, Pledget 1%*
*equivalent to 1% (10 mg/mL) clindamycin
For Topical Use Only.
60 Pledgets
Rx Only
CLINDAMYCIN PHOSPHATE clindamycin phosphate solution | |||||||||||||||||||
| |||||||||||||||||||
| |||||||||||||||||||
| |||||||||||||||||||
| |||||||||||||||||||
|
Labeler - Perrigo New York Inc (078846912) |